Prescription drug pricing has become a very hot topic in the last year. The public policy debate began in earnest with the market launch of Gilead’s Hepatitis C cure, Sovaldi, in 2014, sparking a Congressional investigation . Most recently, the price
Read More...
Read the complete post at http://healthaffairs.org/blog/2015/08/20/biopharmaceuticals-pricing-for-clinical-value-and-in-market-risk/
Posted
Aug 20 2015, 01:39 PM
by
Health Affairs Blog
Filed under: Medicare, Featured, Payment Policy, Costs and Spending, Medicaid and CHIP, Drugs and Medical Technology, Gilead, Medicare Part D, 340B Drug Discount program, Biopharmaceuticals, Sovaldi, Big Pharma